All Releases
Ligand Announces Positive Regulatory Opinion in Europe for Revolade for Chronic Immune Thrombocytopenic Purpura
Dec 18, 2009
|
Ligand and Neurogen Amend Merger Agreement
Dec 17, 2009
|
Ligand Presents New Preclinical Data on its Lead SARM Molecule LGD-4033 at the Gerontological Society of America Annual Meeting
Nov 20, 2009
|
Ligand Earns $2 Million in Milestone Payments from Merck & Co., Inc.
Nov 19, 2009
|
Ligand Pharmaceuticals Announces Third Quarter Results
Nov 5, 2009
|
Ligand's JAK3 Research Collaboration Extended by Pfizer
Nov 5, 2009
|
Ligand Updates License Agreement with Exelixis
Nov 2, 2009
|
Ligand to Acquire Metabasis for Cash and Contingent Value Rights
Oct 27, 2009
|
Ligand to Hold Third Quarter Results Conference Call on November 5
Oct 26, 2009
|
PROMACTA Awarded 2009 Prix Galien for Best Biotechnology Product
Oct 5, 2009
|
Ligand to Present on October 6th at the Fourth Annual JMP Securities Healthcare Focus Conference
Sep 30, 2009
|
Ligand and GlaxoSmithKline Collaboration Identifies New Compound
Sep 28, 2009
|
Ligand Presents to Investors at Thomas Weisel Partners Healthcare Conference
Sep 9, 2009
|
Ligand to Present at Thomas Weisel Partners on September 9
Aug 26, 2009
|
Ligand to Acquire Neurogen for Stock and Contingent Value Rights
Aug 24, 2009
|
Ligand Terminates Long-Term Lease Obligation
Aug 10, 2009
|
Ligand Pharmaceuticals Announces Second Quarter Results
Aug 3, 2009
|
Ligand and Organon Mutually Terminate Collaboration and License Agreement
Jul 30, 2009
|
Ligand to Hold Second Quarter Results Conference Call on August 3
Jul 23, 2009
|
Ligand Licenses Patents for Desulfated Heparin Technology to ParinGenix
Jun 25, 2009
|
|
|
